Sanofi Plaquenil petition asks FDA to set biostudy guidance; Copley generic is target of state petitions.
Executive Summary
PLAQUENIL BIOSTUDIES REQUIRE "ADEQUATE ASSAY SENSITIVITY," SANOFI WINTHROP maintains in a citizen petition filed with FDA Jan. 20. The firm "requests that FDA adopt bioequivalence testing guidance for hydroxychloroquine that assures adequate assay sensitivity and separation of the major metabolites to demonstrate that these metabolites do not co-elute with the parent compound during chromatographic separation," the petition states. Sanofi, which bought out its joint venture with Sterling Oct. 1, markets the innovator hydroxychloroquine product Plaquenil for rheumatoid arthritis and other indications.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth